Patents by Inventor Paul O. Zamora
Paul O. Zamora has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210347838Abstract: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.Type: ApplicationFiled: July 19, 2021Publication date: November 11, 2021Applicants: Ferring B.V., Brookhaven Science Associates, LLCInventors: Paul O. ZAMORA, Brent Lee ATKINSON, Xinhua LIN, Louis A. PENA
-
Patent number: 10611810Abstract: Compounds of the present invention of formula I and formula II are disclosed in the specification and wherein the compounds are modulators of Bone Morphogenic Protein activity. Compounds are synthetic peptides having a non-growth factor heparin binding region, a linker, and sequences that bind specifically to a receptor for Bone Morphogenic Protein. Uses of compounds of the present invention in the treatment of bone lesions, degenerative joint disease and to enhance bone formation are disclosed.Type: GrantFiled: January 31, 2008Date of Patent: April 7, 2020Assignee: FERRING INTERNATIONAL CENTER S.A.Inventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin, Kazuyuki Takahashi
-
Patent number: 9670258Abstract: Compounds of the present invention of formula I and formula II are disclosed in the specification and wherein the compounds are modulators of Bone Morphogenic Protein activity. Compounds are synthetic peptides having a non-growth factor heparin binding region, a linker, and sequences that bind specifically to a receptor for Bone Morphogenic Protein. Uses of compounds of the present invention in the treatment of bone lesions, degenerative joint disease and to enhance bone formation are disclosed.Type: GrantFiled: August 18, 2016Date of Patent: June 6, 2017Assignees: Ferring B.V., Brookhaven Science Associates, LLCInventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin, Takahashi Kazuyuki
-
Publication number: 20160376334Abstract: Compounds of the present invention of formula I and formula II are disclosed in the specification and wherein the compounds are modulators of Bone Morphogenic Protein activity. Compounds are synthetic peptides having a non-growth factor heparin binding region, a linker, and sequences that bind specifically to a receptor for Bone Morphogenic Protein. Uses of compounds of the present invention in the treatment of bone lesions, degenerative joint disease and to enhance bone formation are disclosed.Type: ApplicationFiled: August 18, 2016Publication date: December 29, 2016Inventors: Paul O. ZAMORA, Louis A. Pena, Xinhua Lin, Takahashi Kazuyuki
-
Publication number: 20150353615Abstract: Compounds of the present invention of formula I and formula II are disclosed in the specification and wherein the compounds are modulators of Bone Morphogenic Protein activity. Compounds are synthetic peptides having a non-growth factor heparin binding region, a linker, and sequences that bind specifically to a receptor for Bone Morphogenic Protein. Uses of compounds of the present invention in the treatment of bone lesions, degenerative joint disease and to enhance bone formation are disclosed.Type: ApplicationFiled: January 31, 2008Publication date: December 10, 2015Inventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin, Kazuyuki Takahashi
-
Patent number: 8796212Abstract: A composition comprising a synthetic growth factor analog comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analog is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.Type: GrantFiled: July 19, 2011Date of Patent: August 5, 2014Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Brent Lee Atkinson, Xinhua Lin, Louis A. Pena
-
Publication number: 20120309694Abstract: The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: ApplicationFiled: April 24, 2012Publication date: December 6, 2012Applicant: BIOSURFACE ENGINEERING TECHNOLOGIES, INC.Inventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin
-
Patent number: 8227411Abstract: The present invention provides a fibroblast growth factor heparin-binding analog of the formula: where R1, R2, R3, R4, R5, X, Y and Z are as defined, pharmaceutical compositions, coating compositions and medical devices including the fibroblast growth factor heparin-binding analog of the foregoing formula, and methods and uses thereof.Type: GrantFiled: February 23, 2006Date of Patent: July 24, 2012Assignees: BioSurface Engineering Technologies, Incle, Brookhaven and Science AssociatesInventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin, Kazuyuki Takahashi
-
Patent number: 8163717Abstract: The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: GrantFiled: October 6, 2009Date of Patent: April 24, 2012Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin
-
Patent number: 8101570Abstract: A heparin-binding growth factor (HBGF) analog having two substantially similar sequences (homodimeric sequences) branched from a single amino acid residue, where the sequences are analogs of a particular HBGF that binds to a heparin-binding growth factor receptor (HBGFR), or alternatively that bind to a HBGFR without being an analog of any particular HBGF. The homodimeric sequences may be derived from any portion of a HBGF. The synthetic HBGF analog may be an analog of a hormone, a cytokine, a lymphokine, a chemokine or an interleukin, and may bind to any HBGFR. Further provided are preparations for medical devices, pharmaceutical compositions and methods of using the same.Type: GrantFiled: May 24, 2010Date of Patent: January 24, 2012Assignee: BioSurface Engineering Technologies, Inc.Inventors: Kazuyuki Takahashi, Paul O. Zamora, Louis A. Pena, Xinhua Lin
-
Publication number: 20110305741Abstract: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.Type: ApplicationFiled: July 19, 2011Publication date: December 15, 2011Applicant: BIOSURFACE ENGINEERING TECHNOLOGIES, INC.Inventors: Paul O. Zamora, Brent Lee Atkinson
-
Patent number: 7981862Abstract: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.Type: GrantFiled: June 22, 2007Date of Patent: July 19, 2011Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Brent Lee Atkinson
-
Publication number: 20100298218Abstract: A heparin-binding growth factor (HBGF) analog having two substantially similar sequences (homodimeric sequences) branched from a single amino acid residue, where the sequences are analogs of a particular HBGF that binds to a heparin-binding growth factor receptor (HBGFR), or alternatively that bind to a HBGFR without being an analog of any particular HBGF. The homodimeric sequences may be derived from any portion of a HBGF. The synthetic HBGF analog may be an analog of a hormone, a cytokine, a lymphokine, a chemokine or an interleukin, and may bind to any HBGFR. Further provided are preparations for medical devices, pharmaceutical compositions and methods of using the same.Type: ApplicationFiled: May 24, 2010Publication date: November 25, 2010Applicant: BIOSURFACE ENGINEERING TECHNOLOGIES, INC.Inventors: Kazuyuki Takahashi, Paul O. Zamora, Louis A. Pena, Xinhua Lin
-
Patent number: 7820172Abstract: Multi-domain peptides including a heparin-binding peptide sequence covalently linked to a linker sequence, which linker sequence is covalently linked to a trifunctional amino acid residue forming a branch with two arms, with substantially similar (homodimeric) cellular attachment peptide sequences covalently linked, directly or through an intermediate, to each branch arm, where the sequences are cell binding analogs of or derived from laminin or a portion of laminin. Further provided are preparations for medical devices, pharmaceutical compositions and methods of using the same.Type: GrantFiled: June 1, 2007Date of Patent: October 26, 2010Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Kazuyuki Takahashi, Xinhua Lin
-
Publication number: 20100267650Abstract: The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: ApplicationFiled: October 6, 2009Publication date: October 21, 2010Applicant: BIOSURFACE ENGINEERING TECHNOLOGIES, INC.Inventors: PAUL O. ZAMORA, LOUIS A. PENA, XINHUA LIN
-
Patent number: 7700563Abstract: The invention provides synthetic heparin-binding growth factor analogs having at least one peptide chain, and preferably two peptide chains branched from a dipeptide branch moiety composed of two trifunctional amino acid residues, which peptide chain or chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a linker, which may be a hydrophobic linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: GrantFiled: August 19, 2003Date of Patent: April 20, 2010Assignees: BioSurface Engineering Technologies, Inc., Brookhaven Science AssociatesInventors: Louis A. Pena, Paul O. Zamora, Xinhua Lin, John D. Glass
-
Patent number: 7671012Abstract: Formulations, kits and methods for bone or cartilage repair, including treatment of osteogenic defects, including formulations of synthetic heparin-binding growth factor analogs, non-ionic polymers, gelling agents and calcium-containing agents.Type: GrantFiled: February 23, 2006Date of Patent: March 2, 2010Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Sarah Campion
-
Patent number: 7598224Abstract: The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: GrantFiled: February 24, 2005Date of Patent: October 6, 2009Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin
-
Publication number: 20090143566Abstract: The invention provides synthetic heparin-binding growth factor analogs of formulas I or II as given in the specification, having two peptide chains branched from a dipeptide branch moiety composed of at least one and preferably two trifunctional amino acid residues, which peptide chain or chains bind a heparin-binding growth factor receptor. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: ApplicationFiled: October 29, 2007Publication date: June 4, 2009Applicant: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin
-
Patent number: RE47115Abstract: A composition comprising a synthetic growth factor analog comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analog is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.Type: GrantFiled: August 5, 2016Date of Patent: November 6, 2018Assignees: Ferring B.V.Inventors: Paul O. Zamora, Brent Lee Atkinson, Xinhua Lin, Louis A. Pena